Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03643614
Recruitment Status : Recruiting
First Posted : August 23, 2018
Last Update Posted : December 5, 2018
Sponsor:
Information provided by (Responsible Party):
South Ural State Medical University

Brief Summary:

A new strategy for treatment of late radiation damage is to develop methods aimed at stimulating the regenerative capabilities of irradiated tissues. Since the main pathogenetic mechanism of the development of late radiation damage is the death or damage of the replicative mechanism of stromal cells (SC), a justified approach can be considered as transplantation of intact SC. Currently, there is convincing evidence in the scientific literature that the injection of intact autologous SCs into the zone of fibrosis surrounding the chronic radiation ulcer leads to the healing of a wound defect.

An Initiative Clinical Trial. Introduction of autologous regenerative cells of adipose tissue for the treatment of post-irradiation vaginal-rectal fistula. It is assumed that patients will be included in the project within 12 months; the monitoring of each patient will last for 6 months; the total duration of the clinical part of the study will be 18 months; The total duration of the clinical trial including the preparatory phase and the writing of the report is about 24 months. It is assumed that at least 16 patients aged 20 to 75 years who have verified diagnosis of post-irradiation vaginal-rectal fistula will participate in this pilot project. The aims of the clinical trial are to preliminarily assess the safety, effectiveness and quality of life of patients after introducing autologous regenerative cells of adipose tissue for the treatment of post-irradiation vaginal-rectal fistula.


Condition or disease Intervention/treatment Phase
Rectovaginal Fistula Procedure: Injection of autologous regenerative cells of adipose tissue Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Effectiveness and Safety of Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula
Actual Study Start Date : August 1, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fistulas

Arm Intervention/treatment
Experimental: study group
Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
Procedure: Injection of autologous regenerative cells of adipose tissue
Autologous regenerative cells of adipose tissue are injected diffusively in the submucosal layers of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.




Primary Outcome Measures :
  1. Serious adverse events [ Time Frame: 4 weeks after injection of adipose-derived regenerative cells ]
    Frequency, type and severity of serious adverse events (SAE)

  2. Serious adverse reactions [ Time Frame: 4 weeks after injection of adipose-derived regenerative cells ]
    Frequency, type and severity of serious adverse reactions (SAR)


Secondary Outcome Measures :
  1. Changes of fistula size [ Time Frame: 48 weeks after intervention ]
    Intervention impact on dimensions of rectovaginal fistula

  2. Changes in rectovaginal soft tissue density and flexibility [ Time Frame: 48 weeks after intervention ]
    Intervention impact on soft tissue density and flexibility assessed by ultrasound elastography

  3. Quality of life monitoring - 1 [ Time Frame: 48 weeks after intervention ]

    Quality of life estimated by validated questionnaire: The Short Form (36) Health Survey (SF-36). SF-36 is a 36-item, patient-reported survey of patient health.

    The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    The eight sections are:

    • vitality
    • physical functioning
    • bodily pain
    • general health perceptions
    • physical role functioning
    • emotional role functioning
    • social role functioning
    • mental health

  4. Quality of life monitoring - 2 [ Time Frame: 48 weeks after intervention ]
    Quality of life estimated by validated questionnaire. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 with module for proctitis-23 is a questionnaire developed to assess the proctitis-specific quality of life of cancer patients. Each subscale values varies from 1 to 4. Lower values represents better life quality. Total score is computed by summarizing of subscales.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of radiation-induced rectovaginal fistula established at least six months after radiation therapy
  • Absence of oncological disease relapse during whole observation period
  • Absence of rectal and anal cancer
  • Patient have read and signed informed consent

Exclusion Criteria:

  • Contraindications for local/general anesthesia or a history of anesthetic medicines allergy
  • Acute hemorrhoid or anal fissure
  • Acute purulent paraproctitis
  • Inflammatory colon diseases
  • History of extensive posttraumatic or postoperative alterations which causes obstacles to follow protocol examination
  • Chronic sub- or decompensated internal organs diseases
  • Clinically significant laboratory tests abnormalities
  • Conditions that limits patient compliance (dementia, psycho-neurological diseases, drug abuse, alcohol abuse etc.)
  • Patients involved in other clinical trials or taking medications under research during last three months
  • Cancer patients including postoperative chemo- or/and radiotherapy at least three months after surgery
  • Patients with increased activated partial thromboplastin time level 1,8 times above normal
  • Patients who take anticoagulants or took anticoagulants at least one month before including into trial
  • Patients who take or took before investigation glycoprotein inhibitors IIB/IIIA
  • Patients with history of taking medications that influence fatty tissue structure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03643614


Contacts
Layout table for location contacts
Contact: Zhanna Teryushkova, PhD +79128922393 danil-popov97@mail.ru
Contact: Viacheslav Vasilyev, PhD +79634664355 b_b_c_@mail.ru

Locations
Layout table for location information
Russian Federation
South Ural State Medical University Recruiting
Chelyabinsk, Chelyabinsk Oblast, Russian Federation, 454092
Contact: Georgy Dimov, PhD    +79222313585    inlab.chelsma@gmail.com   
Contact: Viacheslav Vasilyev, PhD    +79634664355    b_b_c_@mail.ru   
Principal Investigator: Zhanna Teryushkova, PhD         
Sponsors and Collaborators
South Ural State Medical University
Investigators
Layout table for investigator information
Study Chair: Georgy Dimov, PhD South Ural State Medical University
Study Director: Viacheslav Vasilyev, PhD South Ural State Medical University
Principal Investigator: Zhanna Teryushkova, PhD South Ural State Medical University

Layout table for additonal information
Responsible Party: South Ural State Medical University
ClinicalTrials.gov Identifier: NCT03643614     History of Changes
Other Study ID Numbers: RU SUSMU 310855.210617.1
First Posted: August 23, 2018    Key Record Dates
Last Update Posted: December 5, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by South Ural State Medical University:
adipose derived stromal cells
stromal vascular fraction
mesenchymal stem cells
rectovaginal fistula

Additional relevant MeSH terms:
Layout table for MeSH terms
Fistula
Rectovaginal Fistula
Pathological Conditions, Anatomical
Rectal Fistula
Intestinal Fistula
Digestive System Fistula
Digestive System Diseases
Intestinal Diseases
Gastrointestinal Diseases
Rectal Diseases
Vaginal Fistula
Vaginal Diseases
Genital Diseases, Female